Fig. 3From: TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinomaComparison on the prognosis and predictive biomarkers between TET1-mutated and wild-type patients. A Analysis of the overall survival (OS) in the ICI-treated cohort (MSKCC-COAD), OS (B), and disease-free survival (C) in the non-ICI-treated cohort (TCGA-COAD). D Tumor mutational burden (TMB) levels in the ICI-treated cohort and TMB and neoantigen load in the non-ICI-treated cohortBack to article page